Protein-based microencapsulation for sugar reduction in food and beverages

Overview

NUCAPS Nanotechnology is developing NuGar, a protein-based nanoencapsulation ingredient designed to help food and beverage manufacturers reduce sugar content without sacrificing taste. The technology leverages controlled release of natural sugar in the mouth, enhancing sweetness perception so that less sugar is needed in the final formulation. NuGar follows the same scientific principle as NUCAPS' validated salt-reduction ingredient NuCla, which has demonstrated sodium reductions of 20–38% across twelve food matrices including bread, sauces, processed meats, soups, and cheese.

The solution is built on a proprietary protein-based microencapsulation platform that uses only two ingredients: a vegetal protein and sugar. It is suitable for vegans, non-allergenic, and qualifies as clean-label. The encapsulated powder can be incorporated into a wide range of food matrices and beverages, and it withstands standard thermal industrial treatments. By enabling targeted release in the mouth, NuGar offers manufacturers a simple, natural, and scalable route to meet sugar-reduction targets while preserving consumer taste experiences.

Technical specifications

• Encapsulation matrix: Natural food-grade proteins (such as casein, zein, or soy) that are biocompatible and biodegradable
• Composition: Only two ingredients — vegetal protein plus sugar — with no synthetic polymers, fats, or additives
• Release mechanism: Controlled release in the mouth to intensify sweetness perception, allowing sugar reduction while maintaining taste
• Format: Powder ingredient that can be incorporated into diverse food matrices and beverages
• Processing tolerance: Resistant to thermal industrial treatments used in conventional food manufacturing
• Platform versatility: The same encapsulation technology supports targeted release profiles for gut, colon, stomach, or mouth applications, enabling a broad portfolio of functional ingredients
• Bioavailability enhancement: The underlying NUCAPS platform has demonstrated up to 30 times higher bioavailability compared with conventional delivery methods for encapsulated bioactives

Technology readiness level

NuGar is currently at an early-to-mid stage of development. The underlying protein-based microencapsulation platform and the closely related NuCla salt-reduction ingredient have been validated through pilot tests in twelve food matrices, with documented sodium reductions of 20–38%. The NuGar development plan progresses through three phases: laboratory proof-of-concept with up to thirty prototypes and physicochemical characterization; optimization including stability testing; and pilot-scale production of one-to-ten kilogram batches with industrial testing, regulatory and labeling review, and consumer organoleptic evaluation. The technology is positioned for co-development and pilot partnerships with food and beverage manufacturers seeking clean-label sugar-reduction solutions.